Surgery News - August 2007 - (Page 20)

TYGACIL A POWERFUL PARTNER A first-in-class antibiotic • Expanded broad spectrum of in vitro activity against many gram positives, gram negatives, anaerobes, and methicillin-resistant Staphylococcus aureus (MRSA)1* Simplified empiric management of polymicrobial infections • No dosage modifications necessary for patients with renal impairment1 • Low potential for drug interactions—not metabolized by, and does not inhibit or induce, cytochrome P4501 TYGACIL is indicated for: • The treatment of adults with complicated skin and skin structure infections caused by E. coli, E. faecalis (vancomycin-susceptible isolates only), S. aureus (methicillin-susceptible and -resistant isolates), S. agalactiae, S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), S. pyogenes, and B. fragilis • The treatment of adults with complicated intra-abdominal infections caused by C. freundii, E. cloacae, E. coli, K. oxytoca, K. pneumoniae, E. faecalis (vancomycin-susceptible isolates only), S. aureus (methicillin-susceptible isolates only), S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgatus, C. perfringens, and P. micros *The clinical significance of in vitro activity is unknown. www.TYGACIL.com Important Safety Information • To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria. • TYGACIL is contraindicated in patients with known hypersensitivity to tigecycline. • TYGACIL should be administered with caution in patients with known hypersensitivity to tetracycline class antibiotics. • Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis has been reported with the use of TYGACIL. • In clinical trials, the most common treatment-emergent adverse events in patients treated with TYGACIL were nausea (29.5%) and vomiting (19.7%). • TYGACIL may cause fetal harm when administered to a pregnant woman. • The safety and effectiveness of TYGACIL in patients below age 18 and lactating women have not been established. • Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening. • The use of TYGACIL during tooth development may cause permanent discoloration of the teeth. TYGACIL should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated. Please see brief summary of Prescribing Information on adjacent page. Reference: 1. TYGACIL® (tigecycline) Prescribing Information, Wyeth Pharmaceuticals Inc. © 2006, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101 121145-01 http://www.TYGACIL.com http://www.TYGACIL.com

Table of Contents Feed for the Digital Edition of Surgery News - August 2007

Contents Drug Developments News From the College Thoracic Surgery Head & Neck Surgery

Surgery News - August 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.